Tuesday, June 23, 2015 10:55:19 AM
The J&J news is probably already built into the share price. You may seek a spike to a quarter or so (if you are lucky), but that is about it.
Think about it. All eggs are in one basket here. DECN talks about other business models/products, but I think that is just fluff. They didn't even bother to proofread the language for the "Discretion Messenger" product (see link below). Embarrassing, but par for the proverbial course here.http://www.pharmatechdirect.com/products.html
Let's not forget the negative financing issues here too. DECN is in bed with multiple hedge funds. Hedge funds that likely will short DECN, and can buy back to cover when profitable. A truly cake & eat it too scenario for the hedge funds. Further, the "special" deals for these hedge funds include below market DECN shares. Below market as in .00006/share in some cases. That's right, .00006/share. How nice for them, extremely dilutive for the small DECN shareholder like yourself.
Plus, I believe this DECN management is incompetent. They rarely communicate with the shareholder. A bad omen.
This is why I believe the DECN share price will continue to sink.
Alliance Creative Group (ACGX) Releases Q2 2024 Financial and Disclosure Report with an increase of over $130,000 in Net Income from Q2 2023 to Q2 2024 • ACGX • Aug 14, 2024 8:30 AM
Avant Technologies Unveils AI-Powered Healthcare Infrastructure to Deliver Intelligent Healthcare Solutions • AVAI • Aug 14, 2024 8:00 AM
SANUWAVE Announces Record Quarterly Revenues: Q2 FY2024 Financial Results • SNWV • Aug 13, 2024 7:11 AM
Kona Gold Beverages, Inc. Nears Completion of Reverse Merger with New Candidate • KGKG • Aug 12, 2024 10:00 AM
Maybacks Global Entertainment and DigiTrax Entertainment Sign Agreement to Broadcast "Karaoke Cloud" on iDreamCTV • AHRO • Aug 12, 2024 8:45 AM
HealthLynked Partners with RxSpark to Enhance Medication Access and Management for Patients • HLYK • Aug 12, 2024 8:00 AM